CDMO Rentschler Biopharma began its expansion project to grow its U.S. footprint and establish a Center of Excellence in North America by placing a single-use bioreactor into the 93,000 square foot facility in Milford, MA that the company bought from Shire earlier this year.

The XDR-500 bioreactor, with a working volume of 100-500 L and downstream process capabilities of 2-8 g/L, is part of a GMP facility suite concept where the system, planned to be client-ready in mid-2020, is currently being prepared for technology transfer. The Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, e.g., multispecific antibodies, according to Rentschler.

Further expansion planning includes another building for large-scale manufacturing, which will also be for single-use bioreactor processing as well as lab capacity for new modalities. Both, in Europe and the U.S., Rentschler Biopharma will be able to leverage its client-centric approach and expertise in advanced technologies to facilitate the “robust and scalable production of complex biomolecules,” says Jesús Zurdo, PhD, senior vp innovation and venture partnerships, Rentschler Biopharma.

This site uses Akismet to reduce spam. Learn how your comment data is processed.